The latest price trends of Lemborexant and analysis of price differences in domestic and foreign markets

Lemborexant is a new dual-receptor antagonist (DORA), mainly used to treat insomnia by antagonizing melatonin receptors in the brain (MT1 and MT2), regulate the sleep-wake cycle, thereby improving the difficulty in falling asleep and the ability to maintain sleep. The drug shows good efficacy in improving sleep quality with relatively mild side effects, providing a new treatment option for patients with chronic insomnia.

In the domestic market, the original drug Lebrasin has recently been launched under the trade name Dayvigo (Dayvigo), but it has not yet been included in medical insurance. Therefore, patients have to pay for it at their own expense when purchasing it domestically, and the price is relatively high, usually based on hospital pharmacy pricing and dosage specifications. Since it is not yet covered by medical insurance, patients with greater financial pressure may consider waiting for price adjustments or other subsidy policies to be introduced.

In overseas markets, the prices of Lebraxen original drugs vary. For example, the Japanese version of the original drug is priced at about RMB 1,000, which is relatively low compared to the pricing in the U.S. market, but still falls within the price range of mid-to-high-end drugs. At present, there are no generic drugs of Leborexon currently available in overseas markets, which means that the original drug is still the main way for patients to obtain the drug, and the price is also maintained at a high level.

Taken together, there are obvious price differences for Lebrasin in domestic and foreign markets. Domestic patients need to bear high costs when purchasing original drugs, while prices in some overseas areas are relatively cheap. However, generic drugs have not yet appeared, and it is impossible to reduce costs through generic drugs in the short term. In the future, if Leborexan is included in domestic medical insurance or generic drugs are launched, it will help reduce the financial burden on patients and improve the accessibility of the drug. When using it, patients should consider the doctor's guidance and their own financial situation to choose a reasonable purchase channel.

Reference link:https://www.drugs.com